Track sentiment, discussions and live quotes, post ideas and see what real traders are doing

Vikings proposed stock and convertible-note offerings have become the main focus after positive VK2735 weight-loss maintenance data fueled a rally. Traders are divided over the dilution and whether the raise signals no near-term buyout, versus the added funding runway for development and commercialization strengthening Vikings position.

SpaceX shares are under pressure amid concerns about an upcoming lockup expiration adding to available share supply and COO Gwynne Shotwells disclosed planned stock sale. Bears see insider selling and the companys lofty valuation as reasons for caution, while bulls argue the sale was preplanned and are buying the dip.

McDonalds shares sold off after managements investor-day outlook pointed to persistent inflation and weak restaurant traffic, while its multiyear growth plan calls for substantial restaurant and franchisee investment. Traders debate whether the decline is an overreaction and a buying opportunity or a sign that high prices and softer consumer demand will continue to weigh on the business.

Large, unusual October call activity is drawing attention to Unity, with traders debating whether the trades signal a bullish bet or reflect call sales and hedging. Buyout, Meta-event, and Roaring Kitty theories are circulating, but remain speculation rather than confirmed catalysts.

FDA scrutiny and compliance concerns around Hims GLP-1 and compounded weight-loss offerings are weighing on sentiment, while traders cite Australia expansion and potential peptide offerings as growth offsets. The community is split between concerns about regulatory risk and frustration with repeated failed breakouts, and bullish views that new growth opportunities could eventually revive the stock.

GRAIL is drawing attention as an FDA advisory panel reviews Galleri, its multi-cancer blood-screening test, with trading halted during the proceedings. Traders are split between optimism about favorable FDA briefing materials and public testimony and concern that panel questions about accuracy and the early detection designation could limit Medicare coverage, even if the test wins support.

BlackBerrys first Alloy Kore design win with Daimler TruckVolvo venture Coretura is drawing attention alongside upcoming quarterly results. Traders see growth potential for QNX, while others are frustrated by the muted share-price response and want evidence that the backlog can convert into revenue.

Arcturuss OTC-deficiency Phase 2 update and pipeline announcement, including plans for ARCT-2601 with LUNAR 2.0 and its myNEO acquisition, are driving discussion. Traders see the data and delivery technology as encouraging, while others are concerned about shifted program timelines and the added spending.

POETs new investor presentation has drawn criticism for offering refreshed marketing material rather than the concrete September commercial or production updates traders were expecting, particularly confirmation of orders and shipments. The community is split between bullish views on its wafer-scale photonics technology and manufacturing potential, and frustration over the lack of verifiable sales progress and management communication.

Traders are circulating independent testing claims that Metas Muse agent routes a meaningful share of traffic through Fastly, particularly interactive browser tasks, fueling an AI-edge infrastructure re-rating narrative. Bulls see potential benefit from agentic AI and Fastlys edge and security offerings, while skeptics question whether the traffic data will translate into durable revenue and warn that the sharp rally may fade.